Discovery of quinolinediones exhibiting a heat shock response and angiogenesis inhibition

Journal of Medicinal Chemistry

Volumn 51, Issue 8, 2008, Pages 2492-2501

  Hargreaves, Robert H J ^a   David, Cynthia L ^b   Whitesell, Luke J ^c   LaBarbera, Daniel V ^a   Jamil, Akmal ^a   Chapuis, Jean C ^a   Skibo, Edward B ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 AZIRIDINYL 2 BIPHENYLQUINOLINE 5,8 DIONE; AMINOQUINOLINE DERIVATIVE; AZIRIDINYLBENZOQUINONE DERIVATIVE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR;

AMINO TERMINAL SEQUENCE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING COMPETITION; BINDING SITE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CYTOSTASIS; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; FIBROBLAST CULTURE; HEAT SHOCK RESPONSE; HUMAN; HUMAN CELL;

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITORS; BINDING SITES; CELL LINE; GREEN FLUORESCENT PROTEINS; HEAT-SHOCK RESPONSE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; QUINOLINES;

EID: 43049129637     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7014099     Document Type: Article

References (30)

1. Vinogradov, S.; Roig, V.; Sergueeva, Z.; Nguyen, C. H.; Arimondo, P.; Thuong, N. T.; Bisagni, E.; Sun, J. S.; Helene, C.; Asseline, U. Synthesis and binding properties of oligo-2′-deoxyrihonucleotidcs conjugated with triple-helix-specific intercalatnrs: Benzo[e] and benzoc(G] pyridoindoles. Bioconjugate Chem. 2003, 14, 120-135.
2. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8, S55-S61.
3. Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity. Invest. New Drugs 1999, 17, 361-373.
4. Andrus, M. B.; Meredith, E. L.; Simmons, B. L.; Sekhar, B. B. V. S.; Hicken, E. J. Total synthesis of (+)-geldanamycin and (-)-o-quinogeldanamycin with use of asymmetric ami- and syn-glycolate aldol reactions. Org. Lett. 2002, 4, 3549-3552.
5. Andrus, M. B.; Meredith, E. L.; Sekhar, B. B. V. S. Synthesis of the left-hand portion of geldanamycin using an antiglycolaie aldol reaction. Org. Lett. 2001, 3, 259-262.
6. Nimmanapatti, R.; OBryan, E.; Bhatta, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin towers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001, 61, 1799-1804.
7. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
8. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299.
9. Lucas, B; Roser, N; Chiosis, G. Facile synthesis of a library of 9-alkyl-8-benzyl-9H-purin-6-ylainine derivatives. J. Comb. Chem. 2001, 3, 518-20.
10. Hargreaves, R.; David, C. L.; Whitesell, L.; Skibo, E. B. Design of quinolinedione-based geldanamycin analogues. Bioorg. Med. Chem. Lett. 2003, 13, 3075-3078.
11. Paull, D. K.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
12. Sausville, E. A., Zaharevitz, D.; Gussio, R.; Meijer, L.; Louarn-Leost, M.; Kunick, C.; Schultz, R.; Lahusen, T.; Headlee, D.; Stinson, S.; Arbuck, S. G.; Senderowicz, A. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target. Pharmacol. Ther. 1999, 82, 285-292.
13. Showalter, H. D. H.; Pohlmann, G. An improved synthesis of 4,7-dimethoxy-1H-indole. Org. Prep. Proced. Int. Briefs 1992, 24, 484-488.
14. Marcu, M. G.; Schulte, T. W.; Neckers, L. J. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 2000, 92, 242-248.
15. Whitesell, L.; Mimnaugh, E. G.; DeCosta, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotien complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8324-8328.
16. Bagatell, R.; Paine-Murricta, G. D.; Taylor, C. W.; Pulcini, E. J.; Akinaga, S.; Benjamin, I. J.; Whitesell, L. Induction of a heat shock factor I-dependent stress response alters the cytotoxic activity of Hsp90-binding agents. Clin. Cancer Res. 2000, 6, 3312-3318.
17. Boyd, M. R. Principles and Practices of Oncology (PPO updates); J.B. Lippincott: Phildelphia. PA, 1989: pp 1-12.
18. Lanza, D. L.; Yost, G. S. Selective dehydrogenation/oxygenation of 3-methylindole by cytochrome P450 enzymes. Drug Metab. Dispos. 2001, 29, 950-953.
19. Bassett, S.; Urrabaz, R.; Sun, D. Cellular response and molecular mechanism of antitumor activity by leinamycin in MiaPaCa human pancreatic cancer cells. Anti-Cancer Drugs 2004, 15, 689-696.
20. Thompson, J. E.; Thompson, C. B. Putting the rup on akt. J. Clin. Oncol. 2004, 22, 4217-4226.
21. Xing, C.; Skibo, E. B.; Dorr, R. T. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: Structure - activity relationships for cytotoxicity and antitumor activity. J. Med. Chem. 2001, 44, 3545-3562.
22. Ross, D. T.; Scherf, U.; Eisen, M. B.; Perou, C. M.; Rees, C.; Spellman, P.; Iyer, V.; Jeffrey, S. S.; Van De Rijn, M.; Waltham, M.; Pergamenschikov, A.; Lee, J. C. E.; Lashkari, D.; Shalon, D.; Myers, T. G.; Weinslein, J. N.; Bolstein, D.; Brown, P. O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 2000, 24, 227-235.
23. Itokawa, H.; Matsumoto, K.; Morita, H.; Takeya, K. Cytotoxic naphthoquinones from Mansoa alliacea. Phytocliemistry 1992, 31, 1061-2.
24. Turowski, P.; Franckhauser, C.; Morris, M. C.; Vaglio, P.; Fernandez, A.; Lamb, N. J. Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol. Biol. Cell 2003, 14, 2984-2998.
25. Murphy, P. V.; Pitt, N.; O'Brien, A.; Enright, P. M.; Dunne, A.; Wilson, S. J.; Duane, R. M.; O'Boyle, K. M. Identification of novel inhibitors of fibroblast growth factor (FGF-2) binding to heparin and endothelial cell survival from a structurally diverse carhohvhrid library. Bioorg. Med. Chem. Lett. 2002, 12, 3287-3290.
26. Aviezer, D.; Seddon, A. P.; Wildey, M. J.; Bohlen, P.; Yayon, A. Development of a high-throughput screening assay for inhibitors of fibroblast growth factor-receptor-heparin interactions. J. Biomol. Screen. 2001, 6, 171-177.
27. Manetti, F.; Corelli, F.; Botta, M. Fibroblast growth factors and their inhibitors. Curr. Pharm. Des. 2000, 6, 1897-1924.
28. Nam, N. H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem. 2003, 10, 1697-1722.
29. Loneragan, G. H.; Gould, D. H.; Mason, G. L.; Garry, F. B.; Yost, G. S., Lanza, D. L.; Miles, D. G.; Hoffman, B. W.; Mills, L. J. Association of 3-methyleneindolenine, a toxic metabolite of 3-methylindole, with acute interstitial pneumonia in feedlot cattle. Am. J. Vet. Res. 2001, 62, 1525-1530.
30. Ghodousi, A.; Huang, X.; Cheng, Z.; Skibo, E. B. Pyrrolobenzimidazoles (PBIs) linked to heterocycles and peptides. Design of DNA base pair specific phosphate hydrolyzing agents and novel cytotoxic agents. J. Med. Chem. 2004, 47, 90100.